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EVOLUTION OF PATIENTS WITH AIDS AFTER cART: CLINICAL AND LABORATORY EVOLUTION OF 
PATIENTS WITH AIDS AFTER 48 WEEKS OF ANTIRETROVIRAL TREATMENT 
Ana Esther Carvalho Gomes FUKUMOTO, Cristiano Claudino OLIVEIRA, Karen Ingrid TASCA & Lenice do Rosário de SOUZA
SUMMARY
Combination Antiretroviral Therapy (cART) aims to inhibit viral replication, delay immunodeficiency progression and improve 
survival in AIDS patients. The objective of this study was to compare two different schemes of cART, based on plasma viral load (VL) 
and CD4+ T lymphocyte count, during 48 weeks of treatment. For this purpose, 472 medical charts of a Specialized Outpatient Service 
were reviewed from 1998 to 2005. Out of these, 58 AIDS patients who had received a triple drug scheme as the initial treatment were 
included in the study and two groups were formed: Group 1 (G1): 47 individuals treated with two nucleoside reverse-transcriptase 
inhibitors (NRTI) and one non-nucleoside reverse-transcriptase inhibitor; Group 2 (G2): 11 patients treated with two NRTI and one 
protease inhibitor. In G1 and G2, 53.2% and 81.8% respectively were patients with an AIDS-defining disease. The T CD4+ lymphocyte 
count increased progressively up until the 24th week of treatment in all patients, while VL became undetectable in 68.1% of G1 and 
in 63.6% of G2. The study concluded that the evolutions of laboratory tests were similar in the two treatment groups and that both 
presented a favorable clinical evolution.
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INTRODUCTION
AIDS is characterized by severe immunosuppression associated 
with the appearance of opportunistic infections and certain types of 
neoplasias1. There were 608,230 cases officially reported in Brazil from 
1980 to June 2011, 56% of which were identified in the southeastern 
region of the country20.
Combination Antiretroviral Therapy (cART) aims to inhibit viral 
replication, delay the progression of immunodeficiency and thereby 
restore immunity, albeit partially, in order to combat or prevent the 
emergence of opportunistic infections, thus increasing patient survival 
and improving quality of life. This tendency is observed throughout the 
world by declines in morbidity and mortality among AIDS patients26,27. 
The risk of progression of HIV infection to the development of AIDS 
or to death is initially related to an elevated HIV viral load (VL), and 
subsequently to a low count of CD4+ T lymphocytes3,4. These markers are 
considered the principal to evaluate the clinical status of the patient and 
to monitor and indicate the start of cART19, following recommendations 
specific to each country, which have been changed over time21,22. 
Currently, the initial therapy must include at least three drugs: two 
nucleoside reverse-transcriptase inhibitors (NRTI) associated with one 
non-nucleoside reverse-transcriptase inhibitor (NNRTI) or with one 
protease inhibitor (PI), preferentially with administration of ritonavir for 
pharmacokinetic enhancement. Schemes with NNRTI are suggested as 
the first option for patients naïve to treatment who start cART21. 
Not all patients under cART exhibit a rise in CD4+ T cell counts 
despite viral suppression11,12,38,39. This observation has been assigned to 
factors related to pre-therapy CD4+ T counts and VL, age at treatment 
initiation and time to reach viral suppression after the start of therapy. 
It is possible that cumulative VL during cART may also influence the 
recovering of CD4+ T counts and the risk of AIDS-defining events, 
suggesting that therapeutic schemes which result in a faster reduction 
and sustained suppression of the viral load could also lead to a more 
favorable clinical evolution and immune response17.
The occurrence of treatment failure must be promptly diagnosed. 
Failure to respond to a therapeutic scheme may occur for different 
reasons including inadequate compliance, presence of co-morbidities, 
previous viral resistance to one or more therapeutic agents, altered 
gastrointestinal absorption, drug interactions and low potency of the 
ARV scheme21.
 The objective of this study was to compare two different cART 
schemes in patients previously naïve to treatment, according to the 
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achievement of undetectable VL and the increase in CD4+ T lymphocyte 
count, during 48 weeks of treatment.
MATERIAL AND METHODS
In the period from January 1998 to December 2005, 472 medical 
charts from the Specialized Outpatient Service and Day Hospital 
“Domingos Alves Meira” from Botucatu Medical School, Univ. Estadual 
Paulista (UNESP), were selected for the study. Of these, 147 were 
excluded since they were inactive in the Medical File.
The inclusion criteria were patients of both sexes with confirmed 
HIV infection, at least 18 years of age, naïve to cART and who had 
been monitored for at least 48 weeks, with T CD4+ count and VL 
determinations each repeated four times during the period. According 
to these inclusion criteria and because many patients had lost follow up, 
only 58 of the 325 individuals were enrolled in the study. This number 
represented about 15% of the overall patients of the Service.
Data collection was accomplished by retrospective analysis of the 
patients medical charts using a previously elaborated and tested formula, 
considering the following aspects: age, sex, origin, risk factors for HIV 
infection, classification of HIV infection according to the CDC (Centers 
for Disease Control and Prevention)4 system, clinical manifestations 
(diseases associated with AIDS, regardless of CD4+ T cell count), CD4+ T 
cell count, HIV VL determination and the cART scheme. The frequency 
of analysis of clinical and laboratory parameters considered in the study 
were at 04, 12, 24 and 48 weeks after the cART initiation.
The counts of CD4+ T lymphocytes and establishment of CV i.e. 
plasma quantification of HIV-1 RNA were accomplished by the flow 
cytometry technique and by the branched-DNA method respectively, 
during the routine medical visits of patients at the Botucatu Hemocenter, 
UNESP. The results were expressed as absolute numbers per cubic 
millimeter of blood (cells/mm3) and as absolute numbers of virus copies 
RNA per milliliter of plasma and base-10 logarithm (log 10).
The patients were divided into two study groups. Group 1 (G1): 47 
individuals in treatment with two NRTIs and one NNRTI. Group 2 (G2): 
11 patients under treatment with two NRTIs and one PI.
Statistical analysis: Descriptive surveying of sociodemographic 
characteristics, comparison between schemes in relation to the numeric 
variables by means of the Mann-Whitney Test, Fisher’s Exact Test and 
Chi-Square, at a significance level of α = 0.05, to study the association 
between the schemes and the categorical variables. The comparison 
between the moments of laboratory evaluation in each scheme was 
accomplished by the Friedman test, at α = 0.05 significance level. There 
were no missing variables at each key time point.
This project was analyzed and approved by the Research Ethics 
Committee of the Botucatu Medical School, UNESP. 
RESULTS
Fifty-eight patients were studied, 34 (58.6%) were male and 24 
(41.4%) female; the median age was 32.5 years, with a range from 21 
to 65 years.
Table 1 shows the distribution of the subjects of the study based 
on mean age, sex, risk factors for HIV infection, classification of HIV 
infection according to CDC, presence or absence of co-morbidities and 
clinical manifestations prior to cART. There was no statistical difference 
between the two groups in relation to these variables. 
Twenty-four (41.4%) patients were not presenting an AIDS-defining 
disease during the study development, while the majority of them, 34 
(58.6%), had manifestations of mild or severe immunodeficiency, including 
persistent generalized lymphadenopathy, oral and esophageal candidiasis, 
pneumocystosis, toxoplasmosis, tuberculosis, cytomegalovirus, herpes 
zoster, cryptosporidiosis, neurological manifestations of Chagas’ disease, 
recurrent pneumonia, molluscum contagious, strongyloidiasis and 
onychomycosis. 
Thirty-six patients (62.1%) showed one or more of the following 
behavior or co-morbidities at the moment of cART initiation: substance 
abuse, tobacco smoking, alcoholism, hepatitis virus B or C, condyloma 
acuminata, syphilis, peptic ulcer, psoriasis, tinea corporis, depression, 
diabetes mellitus, obesity, dyslipidemia, systemic arterial hypertension, 
osteoporosis, hemorrhagic stroke, panic disorder and mental 
deficiency. 
Table 2 shows the patients’ evolution after 48 weeks of treatment, at 
which point no statistically significant differences were found between 
the two study groups. Clinical improvement of immunodeficiency 
manifestations and laboratory parameters was shown in 13 cases 
(22.4%). However, in five (8.7%) patients, all of them of G1, the clinical 
manifestations had worsened.
The evolution of CD4+ T counts is described in Figure 1, including 
medians of the laboratory results during 48 weeks of monitoring. There 
was no significant difference between the groups in the evaluations at each 
time studied, nor when the 24th and 48th weeks were compared. Despite 
the fact that the CD4+ T counts at the 4th, 12th, 24th and 48th weeks were 
significantly higher than at the pre-treatment phase in G1, this was not 
observed in G2. Furthermore, there was a median gain of 155 cells/mm3 
in all patients; 169 cells/mm3 in G1 and 144 cells/mm3 in G2. 
With regard to the CD8+ T lymphocyte counts, there was no difference 
between the groups at any time or between the times studied in each 
scheme. The medians in G1 and G2 were 723 cells/mm3 (478-1162) 
and 686 cells/mm3 (354-952) respectively in the pre-treatment phase, 
and 789 cells/mm3 (539-1113) and 848 cells/mm3 (480-1452) at the end 
of analysis (data not shown in Tables or Figures).
Figures 2 and 3 reveal the distribution of patients in the two groups 
throughout the 48 weeks according to the CD4+ T lymphocytes count. At 
the end of the 48 weeks, most of the patients of both groups were in the 
range between 200 and 400 cells/mm3, although there was no statistically 
significant difference between the two groups.
The analysis of plasma VL determinations is also shown in these 
Figures. In the first determination after four weeks of treatment, 19 
(36.2%) patients of G1 and two (18.2%) of G2 achieved undetectable 
VL. At the end of the 48-week observation period, 32 (68.1%) patients of 
G1 and seven (63.6%) of G2 presented undetectable VL. No statistically 
significant difference was found between the two groups.
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Table 1
Characterization of 58 patients infected by HIV prior the first scheme of potent antiretroviral treatment 
Characteristics G1 G2 Total
Age (median) 32.0
(IQ 1-3: 28.5 - 39)
40.0
(IQ 1-3: 27 - 44.5)
32.5
(IQ 1-3: 28 - 40)
Sex N (%) N (%) N (%)
Male 27 57.4 07 63.7 34 58.6
Female 20 42.6 04 36.4 24 41.4
Risk factors for HIV 
Heterosexuals 30 63.8 08 72.7 38 65.5
Male Homo/Bisexuals 09 19.1 01 9.1 10 17.2
IV* drug users 04 8.5 02 18.2 06 10.3
Homo/Bi. + IV* drug users 02 4.3 00 00 02 3.4
Blood transfusion 01 2.1 00 00 01 1.7
Occupational accident 01 2.1 00 00 01 1.7
CDC classification 
Stage B1 00 00 01 9.1 01 1.7
Stage B2 05 10.3 00 00 05 8.6
Stage B3 23 48.9 03 27.7 26 44.8
Stage C2 05 10.3 02 18.2 07 12.1
Stage C3 14 29.8 05 45.5 19 31.0
Co-morbidities** 
Presence 32 68.1 04 36.4 36 62.1
Absence 15 31.9 07 63.6 22 37.9
Manifestation of AIDS*** 
Presence 25 53.2 09 81.8 34 58.6
Absence 22 46.8 02 18.2 24 41.4
*IV: Intravenous; **Hepatitis virus B or C, condyloma acuminata, syphilis, peptic ulcer, psoriasis, tinea corporis, depression, diabetes mellitus, obesity, dyslipidemia, 
systemic arterial hypertension, osteoporosis, hemorrhagic stroke, panic disorder and mental deficiency; ***Generalized lymphadenopathy, oral and esophageal can-
didiasis, pneumocystosis, toxoplasmosis, tuberculosis, cytomegalovirus, herpes zoster, cryptosporidiosis, neurochagas, recurrent pneumonia, molluscum contagious, 
strongyloidiasis and onychomycosis. G1: 2 nucleoside reverse transcriptase inhibitors + 1 non-nucleoside reverse transcriptase inhibitor; G2: 2 nucleoside reverse 
transcriptase inhibitors + 1 protease inhibitor. Chi-Square: p > 0.05 (G1 = G2).
Table 2 
Clinical evolution of 58 patients after 48 weeks of antiretroviral treatment 
Evolution
G1 G2 TOTAL
N (%) N (%) N (%)
Absence of C.M.* 04 8.5 02 18.1 06 10.3
Unaltered clinical chart (C.M.) 25 53.2 03 27.3 28 48.2
Clinical improvement 10 21.3 03 27.3 13 22.4
Clinical worsening 05 10.6 00 00 05 8.7
Death 01 2.2 00 00 01 1.7
Abandonment of treatment 02 4.2 03 27.3 05 8.7
*C.M. - Clinical manifestation. G1: 2 nucleoside reverse transcriptase inhibitors + 1 non-nucleoside reverse transcriptase inhibitor; G2: 2 nucleoside reverse transcriptase 
inhibitors + 1 protease inhibitor. Chi-Square: p > 0.05 (G1 = G2).
The median, first, and third quartile of VL quantification in the pre-
treatment phase was 68000 (14350-102641) viral copies/mm3 in G1 and 
6300 (945-134500) in G2. Only in G1 was there a difference between the 
VL at this time and at the 4th (G1: 395 [133-1239] and G2: 1900 [412-
38656]) and 12th weeks (G1: 488 [112-3057] and G2: 730 [171-32591]) 
after starting cART. No difference was found between VL values of the 
pre-treatment phase and after 48 weeks of treatment in both groups (G1: 
8668 [1594-73675]; G2: 14976 [2762-243176]). Nevertheless, patients 
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of G1 who had presented higher levels of viral load at the start of therapy 
showed a greater decrease in these levels after 48 weeks (data not shown 
in Tables or Figures).
DISCUSSION
In the present study, the majority of the patients were between the ages 
of 25 and 49. This is in accordance with previous data reported in Brazil, 
although cases in individuals above 50 years old is increasing20. Males 
were predominant in the study, consistent with the tendency observed in 
the national context, although the growing number of women infected 
by the virus must be considered2,20. 
As for the mechanisms of HIV transmission, most of the patients in 
this study were classified in the heterosexual risk category, regardless of 
gender. In the state of São Paulo, and in Brazil as a whole, individuals 
in this risk category have been predominating in recent years, mainly 
among women2,20.
High potency AIDS therapy schemes are responsible for altering the 
progression of the disease – decreasing both the incidence of opportunistic 
infections and the proportion of deaths – since they produce durable 
immunological responses characterized by a reduction in HIV plasma VL 
levels and an increase in CD4+ T lymphocyte counts in the majority of 
patients24,34,35,37. SCHOOLEY34 described the impact of these treatments 
on AIDS mortality in a review, and exemplified this reality with the study 
of PALELLA et al.27, carried out with 1255 patients from nine cities in the 
United States of America. These authors found a decrease from 29.4% to 
8.8% in the proportion of fatalities among the group of patients with CD4+ T 
counts below 100 cells/mm3 one year after the approval of this new therapy. 
However, the best initial regimen is also related to better prognosis. 
According to LI et al.16 in 2011, immunological and virological responses 
in the first five years after cART initiation strongly influenced these same 
responses in the subsequent 5-7 years. Also, patients who responded well 
to the first or second cART regimens maintained higher CD4+ counts 
and lower HIV RNA than those who switched regimens at least twice. 
In a multicohort study30 in Africa and Asia with 632 patients on second-
line cARV for more than six months, it was reported that almost 20% 
of them displayed WHO clinical, immunological or virological criteria 
of failure after a median of 12 months of follow up, with cumulative 
probabilities showing up to 28% of failures at two years. In contrast to 
the study above, our results showed some clinical worsening or death in 
10.4% of patients after 48 months. 
Furthermore, we observed in the present study that schemes 
containing NNRTI were more frequently used (81%) than those with PI 
(18.9%). These data are similar to those found in a study by SANTOS 
et al.33 in 2009 in the state of Goiás, Brazil, that included 222 patients, 
160 (72%) of whom were using NNRTI, emphasizing the combination 
of zidovudine (AZT), lamivudine (3TC) and efavirenz (EFV). In the 
same country, the findings of CUÉLLAR7 between the years 2002 and 
2003 in Recife in the state of Pernambuco, obtained from monitoring 
69 patients for 12 months, also demonstrated that the use of NNRTI was 
more common in 72.5% of cases and the combination AZT+3TC+EFV 
was the most indicated. In this same study, the authors found nelfinavir 
among the most used PI also with the association AZT and 3TC7. All 
these data are consistent with studies of about 5,000 patients conducted 
in Latin America and the Caribbean, with the indication of NNRTI as part 
of the initial regimen in 84% of them, while EFV was the most frequently 
used drug (58.5%)5. However, in the present study the schemes were not 
differentiated by drug, but rather by drug class only. 
The present study has found an increase in CD4+ T lymphocytes 
counts in both groups. After 12 weeks of treatment, G1 and G2 presented 
an equal mean increase of 141 cells and 144 cells. FERRADINI et al.8 
in Cambodia, Asia, showed that a strong immune reconstitution was 
observed after 24 months (gain of 258 cells/mm3 [IQR: 136- 425]) of 
follow-up on second-line cART regimens. In 2010 in Brazil, a study by 
SANTOS et al.33 that compared these cell counts before and after 36 
months of treatment regardless of the ARV scheme used, demonstrated 
an average increase of 225 T CD4+ cells. The less expressive increase 
in the T CD4+ counts found in our study was probably due to the short 
follow- up period of only a few months. Additionally, the lower CD4+ T 
cells count at cART initiation, which strongly predicts progression in the 
first five years after cART6, could have led to a slower immune restoration, 
together with the high VL values observed in the pre-treatment phase.
G1: 2 nucleoside reverse transcriptase inhibitors + 1 non-nucleoside reverse transcriptase inhibitor; 
G2: 2 nucleoside reverse transcriptase inhibitors + 1 protease inhibitor. Friedmann: p < 0.05 (comparison 
between moments in G1); p > 0.05 (comparison between moments in G2). Mann-Whitney: p > 0.05 (G1 = G2). 
* Groups do not differ statistically, when comparing the different moments in each scheme.
Fig. 1 - Median, 1st and 3rd quartile refer to T CD4+ lymphocytes count by scheme and 
treatment moment. 
G1: 2 nucleoside reverse transcriptase inhibitors + 1 non-nucleoside reverse transcriptase inhibitor; 
G2: 2 nucleoside reverse transcriptase inhibitors + 1 protease inhibitor. PT in the x-axis: pre-treatment. 
Chi-Square: p > 0.05 (G1 = G2). Chi-Square: p > 0.05 (G1 = G2). p value between “viral load undetectable” 
from groups 1 and 2: before treatment, p = 0; 4th week, p = 0.167; 12th week, p = 0.127; 24th week, p = 0.087; 
48th week, p = 0.777.
Fig. 2 and 3 - Distribution of patients from groups 01 (G1) and 02 (G2), according to T 
CD4+ lymphocytes count and the percentage evolution of groups with undetectable viral 
load across 48 weeks of treatment.
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SOUZA et al.37 , in a study between 1996 and 2001 in Botucatu 
City, São Paulo State, Brazil, found a mean increase of CD4+ T cell 
counts in patients treated with a combination of NNRTI that did not 
differ statistically from those of patients treated with PI. In the present 
study, a statistical difference was found only in G1 when comparing 
pre-treatment CD4+ T lymphocyte counts with those after 4, 12, 24 and 
48 weeks of treatment. 
A study from 2004 by ROMANINI et al.32 in Porto Alegre (RS), 
Brazil, with patients treated with NNRTI (AZT + 3TC + EFV) and PI 
(AZT + 3TC + atazanavir) found a significant increase in the CD4+ T cell 
counts in both groups, but no difference when one group was compared to 
the other. In this study, the increase in the number of CD4+ T lymphocytes 
was similar to that found in our study, i.e. a median gain of 144 cells 
in the group treated with PI and 169 cells in the NNRTI-treated group. 
Some authors01,13,27,32,40 have reported better results with triple drug 
schemes containing NNRTI and PI than double AIDS drug schemes. 
Nevertheless, internal comparisons do not indicate any difference in 
the evolution of patients, as observed in the present study wherein both 
schemes were effective in increasing CD4+ T lymphocyte counts, which 
was demonstrated by a percentage increase in the portion of patients with 
more than 200 cells/mm3 throughout the observation period. The CD4+ T 
count was below 200/mm3 before cART in 80.8% of the patients treated 
with NNRTI and 63.6% of those treated with PI. After 48 weeks of cART 
these counts were above 200 cells in 76.6% of the NNRTI group and 
63.6% of the PI group.
With reference to plasma VL after 36 months of cART, SANTOS et 
al.33 found that approximately 80% had results below the limit of detection, 
a proportion higher than that of our study, in which 67.2% of the patients 
achieved undetectable levels after six months of therapy and maintained 
this result until the end of the 48 weeks. However, these are better data 
than those of PINTO NETO et al.29 in 1998 and 1999 in Vitoria (ES), and 
CASEIRO et al.3 between 1997 and 2003 in Santos (SP) who found 50.0% 
and 44.0% respectively. The percentages found in the present study are also 
higher than those registered in the systematic review of BARTLETT et al.1 
in the United States of America in 2001, in which the schemes containing 
PI produced an undetectable viral load in 46.0% of cases versus 51% under 
NNRTI. Still, other authors16 showed that participants using triple NRTI-
cART were significantly less likely to suppress RNA than those using 
PI-cART or NNRTI-cART, in a study that involved individuals who were 
either ART naïve or not at the time of cART initiation.
Nevertheless, it should be emphasized that differences in the 
methodology adopted by various authors hinders comparison, mainly on 
account of the inclusion of patients having already experimented with 
ARV or the maintenance in the study of patients with many changes in 
therapeutic schemes, since the present study included only patients in 
their first cART scheme.
The maintenance of undetectable VL was discussed by CASEIRO et 
al.3. These authors accompanied patients naïve to cART for six years, and 
found that only 27.5% remained with levels below the limit of detection 
after one year of treatment with triple drug schemes, composed of both 
NNRTI and PI. For SILVEIRA et al.36 and CUÉLLAR07, an undetectable 
level as well as its maintenance for the longest possible period of time is 
associated with factors of compliance or non-compliance to treatment7,36 
such as education level, socioeconomic factors, side effects, the number 
of doses of medicaments and the evolution of clinical parameters07. Some 
authors10,16 hypothesized that patient age, HIV-1 disease stage before 
cART initiation, immunological and virological responses to cART 
in the first five years of treatment and types of cART regimens would 
significantly affect later CD4+ count and RNA levels among long-term 
cART users. However, other factors which occur in the early or late stages 
of infection can contribute to the defective responses on these parameters, 
such as low T CD4+ nadir23 and residual viremia results from cellular 
reservoirs despite viral suppression18.
The best time to initiate the treatment and the best choice for a first 
scheme remain frequent topics of discussion in the literature. Some 
studies affirm the prudence of postponing the start of therapy on account 
of its side effects and also because the benefits of the treatment do not 
outweigh the risks of these effects31. According to many authors such as 
FRENCH et al.9, NIXON & LANDAYB25 and KAMAT et al.15, persistent 
chronic inflammation and immune activation are factors potentially 
determinant of morbidity and mortality not associated with AIDS, even 
during effective cART. Thus, it is necessary for these parameters to 
be minimized in order to increase patient survival. Meanwhile, other 
studies21,23 have already indicated its earlier use, since the nadir of CD4+ 
T is considered an important factor for predicting the immune response 
whereas the ARV combinations independently of the initial scheme 
showed similar effects on this recuperation23. In addition to preventing 
immune deterioration23, the early initiation of cART is associated with 
improved control of diseases both related and unrelated to AIDS28. 
It must also be considered that there is a strong correlation between 
VL levels of the infected partner at the moment of transmission and the 
VL values in the acute phase of those recently infected14, which intensifies 
the theory of early initiation of ARVs in order to maintain low VL in 
chronic carriers. 
In fact, due to the unavailability of a new review of medical records 
and the impossibility of performing adjusted analysis, it must be taken 
into account that the small sample size of this study, the retrospective 
design and some baseline differences could result in biased interpretation. 
Hence, larger prospective and long-term evolution studies are needed in 
order to better evaluate the response and durability of each therapeutic 
scheme.
CONCLUSION
The present study has shown a favorable evolution of the therapeutic 
response in up to 48 weeks to the first scheme proposed for individuals 
naïve to cART, but without difference between the use of NNRTI versus PI. 
RESUMO
Evolução de pacientes com AIDS pós cART: evolução clínica 
e laboratorial de pacientes com AIDS após 48 semanas de 
tratamento antirretroviral
A terapia antirretroviral na aids visa inibir a replicação viral, retardar 
a progressão da imunodeficiência e melhorar a sobrevida do paciente. 
O objetivo do estudo foi comparar dois esquemas de tratamentos 
antirretrovirais, quanto à carga viral plasmática (CV) e contagem de 
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linfócitos T CD4+, durante 48 semanas de tratamento, pela revisão de 472 
prontuários no período de 1998 a 2005, em um Serviço de Ambulatórios 
Especializados. Foram incluídos para o estudo 58 pacientes que 
receberam esquema tríplice como terapêutica inicial, os quais formaram 
dois grupos: Grupo 1 (G1): 47 indivíduos em tratamento com dois 
inibidores de transcriptase reversa análogos de nucleosídeos (ITRN) e 
um inibidor de transcriptase reversa não análogo de nucleosídeo; Grupo 
2 (G2): 11 pacientes em tratamento com dois ITRN e um inibidor de 
protease. Entre os pacientes de G1 e G2, 53.2% e 81.8%, respectivamente, 
foram classificados como portadores de aids com doença definidora. A 
contagem de linfócitos T CD4+ aumentou progressivamente até a 24ª 
semana de tratamento, em todos os doentes e, a CV tornou-se indetectável 
em 68,1% dos casos de G1 e em 63,6%, do G2. O estudo concluiu que, em 
ambos os grupos de tratamento, houve evolução laboratorial semelhante 
e essa observação foi compatível com evolução clínica favorável dos 
pacientes estudados. 
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